Stay updated on LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Sign up to get notified when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.

Latest updates to the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoNo Change Detected
- Check20 days agoChange DetectedPage revision updated from v3.2.0 to v3.3.2; no substantive content changes observed in the study details page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check28 days agoChange DetectedRemoved the government funding lapse notice from the page, which warned that updates might not be current and that responses could be delayed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check42 days agoChange DetectedNo significant changes were detected; the page content and layout appear unchanged.SummaryDifference0.4%

- Check71 days agoChange DetectedUpdated site notice about funding-related operating status and a new v3.2.0 release; removed the previous v3.1.0 tag.SummaryDifference4%

- Check78 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

- Check92 days agoChange DetectedVersion bump from v3.0.1 to v3.0.2 and removal of the Back to Top control; overall, a minor update with no substantive changes to core content.SummaryDifference0.2%

Stay in the know with updates to LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the LN-145 + Pembrolizumab in Transitional Cell Cancer Clinical Trial page.